Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12104/71308
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHernandez-Ojeda, J.
dc.contributor.authorCardona-Munoz, E.G.
dc.contributor.authorRoman-Pintos, L.M.
dc.contributor.authorTroyo-Sanroman, R.
dc.contributor.authorOrtiz-Lazareno, P.C.
dc.contributor.authorCardenas-Meza, M.A.
dc.contributor.authorPascoe-Gonzalez, S.
dc.contributor.authorMiranda-Diaz, A.G.
dc.date.accessioned2015-11-19T18:57:52Z-
dc.date.available2015-11-19T18:57:52Z-
dc.date.issued2012
dc.identifier.urihttp://hdl.handle.net/20.500.12104/71308-
dc.description.abstractIntroduction: Diabetic polyneuropathy aetiology is based on oxidative stress generation due to production of reactive oxygen species. Ubiquinone is reduced to ubiquinol and redistributed into lipoproteins, possibly to protect them from oxidation. Aims: To evaluate the impact of oral ubiquinone in diabetic polyneuropathy, and the role of lipid peroxidation (LPO) and nerve growth factor (NGF-β). Methods: We conducted a double-blind, placebo-controlled clinical trial, patients were randomized to ubiquinone (400 mg) or placebo daily for 12 weeks. Main outcomes were clinical scores, nerve conduction studies, LPO, NGF-β and safety. Results: Twenty four patients on experimental group and twenty five on control group met the inclusion criteria (mean age 56 years, 22% male and 78% female, mean evolution of type 2 diabetes mellitus 10.7 years). Significant improvement on experimental vs control group was found in neuropathy symptoms score (from 2.5 ± 0.7 to 1 ± 0.8, p < 0.001), neuropathy impairment score (5.5 ± 4 to 3.1 ± 2.6, p < 0.001), sural sensory nerve amplitude (13.0 ± 6.1 to 15.8 ± 5.1 μV, p = 0.049), peroneal motor nerve conduction velocity (39.7 ± 5.0 to 47.8 ± 4.9 m/s, p = 0.047), and ulnar motor nerve conduction velocity (48.8 ± 6.8 to 54.5 ± 6.1 m/s, p = 0.046). There was a significant reduction of LPO in subjects treated with ubiquinone vs placebo (16.7 ± 8.6 and 23.2 ± 15.8 nmol/mL, respectively) with p < 0.05, and NGF-β did not change (control 66.5 ± 26.7 vs. experimental 66.8 ± 28.4 pg/mL, p = 0.856). No drug-related adverse reactions were reported. Conclusions: Twelve weeks treatment with ubiquinone improves clinical outcomes and nerve conduction parameters of diabetic polyneuropathy; furthermore, it reduces oxidative stress without significant adverse events. © 2012 Elsevier Inc. All rights reserved.
dc.titleThe effect of ubiquinone in diabetic polyneuropathy: A randomized double-blind placebo-controlled study
dc.typeArticle
dc.identifier.doi10.1016/j.jdiacomp.2012.04.004
dc.relation.ispartofjournalJournal of Diabetes and its Complications
dc.relation.ispartofvolume26
dc.relation.ispartofissue4
dc.relation.ispartofpage352
dc.relation.ispartofpage358
dc.subject.keywordDiabetic polyneuropathy; Nerve conduction; Nerve growth factor; Oxidative stress; Ubiquinone
dc.contributor.affiliationHernández-Ojeda, J., Unidad de Investigación Cardiovascular, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Cardona-Muñoz, E.G., Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Román-Pintos, L.M., Unidad de Investigación Cardiovascular, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Troyo-Sanromán, R., Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Ortiz-Lazareno, P.C., Departamento de Inmunología, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico; Cárdenas-Meza, M.A., Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Jalisco, Mexico; Pascoe-González, S., Unidad de Investigación Cardiovascular, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Miranda-Díaz, A.G., Unidad de Investigación Cardiovascular, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
dc.subject.headingIndex Medicus;Adult;Aged;Aged, 80 and over;Diabetic Neuropathies/dt [Drug Therapy];Diabetic Neuropathies/me [Metabolism];Diabetic Neuropathies/pp [Physiopathology];Double-Blind Method;Female;Humans;Lipid Peroxidation/de [Drug Effects];Lipid Peroxidation/ph [Physiology];Male;Micronutrients/ae [Adverse Effects];Micronutrients/pd [Pharmacology];Micronutrients/tu [Therapeutic Use];Middle Aged;Nerve Growth Factor/me [Metabolism];Neural Conduction/de [Drug Effects];Neural Conduction/ph [Physiology];Oxidative Stress/de [Drug Effects];Oxidative Stress/ph [Physiology];Treatment Outcome;Ubiquinone/ae [Adverse Effects];Ubiquinone/pd [Pharmacology];Ubiquinone/tu [Therapeutic Use]
dc.relation.isReferencedByScopus
dc.relation.isReferencedByWOS
dc.relation.isReferencedByMEDLINE
dc.identifier.urlhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84863785480&partnerID=40&md5=205fd4a57b0ee226e58ee6855acb3685
dc.identifier.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22595020
Appears in Collections:Producción científica UdeG (prueba)

Files in This Item:
There are no files associated with this item.


Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.